RE:Catching breathI think it's really a lot of retail investors on the sidelines FOMO fear of missing out on a run. We saw it run to $1.60 before a pullback on speculation.
However, the main catalyst for the recent run up is Viacycte article showing that they spent $100 million dollars on a device for precursor cells that really did not give any great results. Sigilon also failed. You have Vertex dumping cells in portal vein . I think Sva might be getting the lead in this horse race and clinical presentation could provide evidence to back it.
The share price going up like before has nothing to do what management accomplished rather than what the competition did not do. I do agree that for sp to stay here or move higher, it will depend upon management delivering . I have doubts about management but I have faith in Witowski.
Ms Sally